e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Novel studies on bronchodilators and cough
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Protein tyrosin kinase and KCa++ cannel: two faces of the same coin in LABA/LAMA synergy
L. Calzetta (Roma, Rm, Italy)
Source:
International Congress 2017 – Novel studies on bronchodilators and cough
Session:
Novel studies on bronchodilators and cough
Session type:
Oral Presentation
Number:
4407
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Calzetta (Roma, Rm, Italy). Protein tyrosin kinase and KCa++ cannel: two faces of the same coin in LABA/LAMA synergy. 4407
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
A 12-year-old male child with fever, productive cough and sudden onset paralysis
A 41-year-old male with cough productive of yellow sputum and worsening breathlessness
Related content which might interest you:
Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
Source: Eur Respir J 2013; 41: 85-95
Year: 2013
Experience of using Janus kinase inhibitors in COVID-19
Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment
Year: 2021
Hemaglutinin (HA) of H5N1 disturbs cAMP-dependent CFTR channel via activation of janus kinase 3
Source: Annual Congress 2009 - Translational models of lung disease
Year: 2009
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020
Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology
Year: 2007
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis
Source: ERS Lung Science Conference 2020
Year: 2020
A patient with a lazarus effect on tyrosine kinase inhibition
Source: Virtual Congress 2020 – Lung cancer grand round
Year: 2020
Kinase inhibitors
Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD
Year: 2012
LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
Tyrosine Kinase Transmembrane Receptor alterations in NSCLC
Source: ERS Research Seminar
Year: 2015
Tyrosine kinase inhibitors beyond progression: never, intercalating or forever?
Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies
Year: 2015
Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Effect of fudosteine on mucin production
Source: Eur Respir J 2008; 32: 1195-1202
Year: 2008
Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
beta2-Agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway
Source: Eur Respir J 2010; 35: 647-654
Year: 2010
The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema
Source: Eur Respir J 2005; 25: 849-857
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept